Date: 2011-03-22
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) Okairos (Italy)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: Vivalis announced that Okairos has executed a research license agreement to access Vivalis’s EB66® cell line to evaluate the production of a candidate human vaccine. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
